Oxidized Phospholipids, Lp(a) Lipoprotein, and Coronary Artery Disease

This cross-sectional study measured oxidized phospholipid levels on ApoB-100 particles (OxPL/ApoB ratio) and Lp(a) concentration in 504 patients with documented coronary artery disease and controls, demonstrating the relationship between OxPL, Lp(a), and CAD severity.

OxPL/ApoB and Lp(a) were highly correlated (r=0.87), and both were substantially elevated in CAD patients compared with controls. Lp(a) is the primary carrier of OxPL in human plasma — representing approximately 80–90% of total circulating OxPL on ApoB particles. Among patients with established CAD, higher OxPL/ApoB was independently associated with more extensive coronary disease.

This study established the mechanistic link that explains Lp(a)‘s special atherogenicity: Lp(a) particles carry oxidized phospholipids that are biologically active mediators of vascular inflammation, endothelial dysfunction, and macrophage foam cell formation. Standard total cholesterol and LDL-C measurements capture none of this OxPL-mediated biology — it is specific to Lp(a) particles and invisible to conventional lipid panels.

The correlation coefficient between OxPL/ApoB and Lp(a) (r=0.87) means that Lp(a) measurement effectively proxies for OxPL burden, explaining why Lp(a) concentration is the preferred clinical biomarker for this mechanism.

We rate the evidence strong. A carefully characterized cross-sectional study in 504 patients establishing Lp(a) as the principal plasma carrier of oxidized phospholipids and demonstrating OxPL’s association with CAD severity — foundational mechanistic evidence explaining why Lp(a) is more atherogenic per particle than LDL.